International Trade Today is a service of Warren Communications News.
Subscriber Login
Commerce Dept.
to
Refine Category Search
Clear Terms

Search Primer

Multi-word term: Place inside quotes to ensure an exact match together (e.g. "forced labor").

Term list: Separate terms with spaces, not commas or semicolons to find either word (e.g. AD/CVD CBP).

Acronyms: Use all capital letters (e.g., ACE).

Required term: If a term must be included in any resulting articles, prefix it with a plus sign (e.g., tariffs +Canada).

Excluded term: If a term should be excluded from any articles being found, prefix it with a minus sign (e.g., FDA -alert).

Simplest form: Use the simplest form of a term (e.g. "metal" instead of "metals" or "entity list" instead of "entity listing" or "entity listed").

CITA Adding Nylon/Polyester Dobby Weave Fabrics to CAFTA-DR Commercial Availability List
August 2, 2024 |Commerce Dept.

The Committee for the Implementation of Textile Agreements is adding several types of nylon and polyester dobby weave fabric to the "short supply list" in Annex 3.25 of the Dominican Republic-Central America Free Trade Agreement for items not commercially available in a timely manner, it said in a notice. Powers Manufacturing Company, which does business as Powers Athletic, requested the additions in June. The fabrics, classifiable under Harmonized Tariff Schedule subheadings 5407.73.2015, 5407.73.2060, 5407.53.2020 and 5407.53.2060, are being added in unrestricted quantities. Under short supply provisions of CAFTA-DR, fibers, yarns and fabrics listed in Annex 3.25 are provided with tariff preferences under the trade agreement.

BIS to Survey Pharmaceducal Industry, Supply Chains
July 10, 2024 |Commerce Dept.

The Bureau of Industry and Security is preparing to launch a survey of the pharmaceutical industry to gain a better understanding of the “supply chain network that underpins U.S. pharmaceutical manufacturing capabilities,” the agency said in a July 9 news release. BIS will survey hundreds of U.S. manufacturers, distributors, suppliers and customers involved in the U.S. “active pharmaceutical ingredient industrial base” in part to identify supply chain vulnerabilities and better plan for potential supply shortages. The Department of Health and Human Services requested the survey.